ABVC BioPharma flags going-concern doubt in 10-Q, delays BioKey Cayman spinoff

ABVC BioPharma filed prospectus supplements on August 17, 2026 attaching its Form 10-Q for the quarter ended June 30, 2026, which was originally filed with the SEC on August 12, 2026.

The filing discloses financial strain. The company reported a net loss of $2,500,418 for the six months ended June 30, 2026, a working capital deficit of $5,282,776 as of that date, and net cash outflows of $1,138,656 from operating activities over the same period, conditions that the company said create substantial doubt about its ability to continue as a going concern.¹ Management said it may look to operating cash flow, private or public capital raises, and support from related parties and shareholders to address the shortfall, according to the filing.

Separately, the company is in the midst of a corporate reorganization involving its BioKey Cayman subsidiary. On June 22, 2026, ABVC announced plans to partially separate the BioKey Cayman business from ABVC as part of what it called Reorganization Transactions, saying the move was intended to enhance shareholder value.¹ The plan involves two steps: a legal separation of BioKey Cayman, followed by a distribution of BioKey Cayman shares to ABVC shareholders. ABVC intends to distribute approximately 4,500,000 BioKey Cayman ordinary shares, representing about 15% of BioKey Cayman's outstanding shares, to ABVC shareholders on a pro rata basis, after which ABVC is expected to retain roughly 85% of BioKey Cayman and remain its controlling shareholder.¹ The distribution had originally been scheduled for August 3, 2026, but was postponed due to outstanding tax, administrative, and regulatory matters, and a revised date has not yet been set.¹